Ceramides and Atherosclerotic Cardiovascular Disease: A Current Perspective

HomeCirculationVol. 149, No. 21Ceramides and Atherosclerotic Cardiovascular Disease: A Current Perspective No AccessArticle CommentaryRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessArticle CommentaryRequest AccessFull TextCeramides and Atherosclerotic Cardiovascular Disease: A Current Perspective Qingzhang Zhu and Philipp E. Scherer Qingzhang ZhuQingzhang Zhu https://orcid.org/0000-0001-9382-8517 Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas. and Philipp E. SchererPhilipp E. Scherer Correspondence to: Philipp E. Scherer, PhD, University of Texas Southwestern Medical Center, Touchstone Diabetes Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8549. Email E-mail Address: [email protected] Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas. Originally published20 May 2024https://doi.org/10.1161/CIRCULATIONAHA.123.065409Circulation. 2024;149:1624–1626FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Sources of Funding and Disclosures, see page 1626.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Philipp E. Scherer, PhD, University of Texas Southwestern Medical Center, Touchstone Diabetes Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8549. Email philipp.scherer@utsouthwestern.eduREFERENCES1. Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. Ceramides and other sphingolipids as drivers of cardiovascular disease.Nat Rev Cardiol. 2021; 18:701–711. doi: 10.1038/s41569-021-00536-1CrossrefMedlineGoogle Scholar2. Hilvo M, Jylhä A, Lääperi M, Jousilahti P, Laaksonen R. Absolute and relative risk prediction in cardiovascular primary prevention with a modified SCORE chart incorporating ceramide-phospholipid risk score and diabetes mellitus.Eur Heart J Open. 2021; 13:oeab010. doi: 10.1093/ehjopen/oeab010CrossrefGoogle Scholar3. Papazoglou AS, Stalikas N, Moysidis DV, Otountzidis N, Kartas A, Karagiannidis E, Giannakoulas G, Sianos G. CERT2 ceramide- and phospholipid-based risk score and major adverse cardiovascular events: a systematic review and meta-analysis.J Clin Lipidol. 2022; 16:272–276. doi: 10.1016/j.jacl.2022.02.001CrossrefMedlineGoogle Scholar4. Akawi N, Checa A, Antonopoulos AS, Akoumianakis I, Daskalaki E, Kotanidis CP, Kondo H, Lee K, Yesilyurt D, Badi I, et al. Fat-secreted ceramides regulate vascular redox state and influence outcomes in patients with cardiovascular disease.J Am Coll Cardiol. 2021; 77:2494–2513. doi: 10.1016/j.jacc.2021.03.314CrossrefMedlineGoogle Scholar5. Hadas Y, Vincek AS, Youssef E, Żak MM, Chepurko E, Sultana N, Sharkar MTK, Guo N, Komargodski R, Kurian AA, et al. Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction.Circulation. 2020; 141:916–930. doi: 10.1161/CIRCULATIONAHA.119.041882LinkGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetails May 21, 2024Vol 149, Issue 21 Advertisement Article InformationMetrics © 2024 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.065409PMID: 38768269 Originally publishedMay 20, 2024 Keywordscardiovascular diseasesceramidesrisk factorsPDF download Advertisement SubjectsClinical StudiesLipids and CholesterolTranslational Studies